Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
View Patent ↗The present invention relates to compositions and methods for diagnosing, monitoring and/or treating an autoimmune or chronic inflammatory disease. In particular, the present invention provides methods for diagnosing, monitoring and treating an autoimmune disease (e.g., rheumatoid arthritis) or chronic inflammatory disease (e.g., systemic lupus erythematosus) based on detecting or altering (e.g., altering expression or methylation status of) autoimmune or chronic inflammatory disease proteins (e.g., CD70 and CD40L). The present invention also provides kits for detecting methylation status of autoimmune or chronic inflammatory disease proteins (e.g., CD70 and CD40L) and for diagnosing, monitoring and/or treating autoimmune or chronic inflammatory diseases.
1. A method for diagnosing or monitoring an autoimmune or chronic inflammatory disease, wherein said autoimmune or chronic inflammatory disease is systemic lupus erythematosis or rheumatoid arthritis, in a subject, comprising:
a) providing nucleic acid from a subject; and
b) detecting methylation status of CD40L in said nucleic acid;
wherein said methylation status of CD40L is correlated with the presence or absence of said autoimmune or chronic inflammatory disease in said subject.
2. The method of claim 1 , wherein said method detects methylation status of the 5′ untranslated region of CD40L.
3. The method of claim 1 , further comprising detecting methylation status of one or more of CD70, perform CD11a, CD11c, IgE FCRγ1, and CD30.
4. The method of claim 1 , wherein said detecting comprises using a kit comprising reagents sufficient for detecting methylation status of CD40L in a subject.
5. The method of claim 1 , wherein said method detects methylation status of the −350 to −400 region of CD40L.
6. The method of claim 1 , wherein said method detects methylation status of the 125 to −400region of CD40L.
7. The method of claim 5 , wherein the presence of demethylated CD40L in said subject, when compared to the methylation of CD40L in a healthy subject, is indicative of the presence of an autoimmune or chronic inflammatory disease.
8. The method of claim 6 , wherein the presence of demethylated CD40L in said subject, when compared to the methylation of CD40L in a healthy subject, is indicative of the presence of an autoimmune or chronic inflammatory disease.
9. The method of claim 1 , wherein said detecting comprises use of a polymerase chain reaction.
10. The method of claim 9 , wherein said polymerase chain reaction is methylation sensitive.
11. The method of claim 1 , wherein said detecting comprises differential antibody binding, oligonucleotide binding assays, or use of a microarray.
12. The method of claim 1 , wherein said detecting comprises restriction enzyme digestion.
13. The method of claim 4 , wherein said kit comprises a positive control that indicates CD40L methylation status.